Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

AbbVie

Amgen

AstraZeneca

Bristol-Myers

Cerevel Therapeutics Holdings Inc

Horizon Pharma

ImmunoGen

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer.

Mirati's lung cancer drug gets EU's regulatory backing

SAN DIEGO, Calif. and ZUG, Switzerland , Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Mirati will receive $58.00 in cash for each share of Mirati that they own as well as one non-tradeable Contingent Value Right per Mirati share, entitling its hold.

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates. "We are pleased to share the significant progress made during the third quarter of 2023, highlighted by the advancement of our robust pipeline of targeted oncology programs and continued launch execution of KRAZATI®," said Charles Baum, M.D.

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

SAN DIEGO and ZUG, Switzerland , Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy. "KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati Therapeutics, including its oncology drug Krazati, is expected to support long-term shareholder returns. Mirati Therapeutics has a promising pipeline of drugs, including MRTX1719, and potential expanded indications that could increase sales.

Bristol-Myers Squibb Acquisition Of Mirati Makes Sense

SAN DIEGO , Oct. 17, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study evaluating adagrasib combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation at the European Society of Medical Oncology Congress (ESMO) 2023. These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly

Point Biopharma Global

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Mirati Therapeutics Inc (NASDAQ:MRTX) stock is dropping today, after news that Bristol-Myers Squibb (BMY) will acquire the company for up to $5.8 billion.

Analysts Target Biotech Name on Buyout Buzz

Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing.

Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics

Bristol-Myers Squibb (BMY) moved to expand its reach into cancer-fighting drugs by buying Mirati Therapeutics (MRTX) in an all-cash deal for what could total $5.8 billion.

Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio

Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.

Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball bid.

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid

MILWAUKEE , Oct. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Mirati (Nasdaq: MRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb. Click here to learn how to join the action https://www.ademilaw.com/case/mirati-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb

The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb's best-selling products.

Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion

Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to diversify Bristol's cancer treatment offerings and mitigate anticipated revenue losses due to upcoming patent expirations.

Bristol-Myers Squibb enahnces oncology portfolio in deal worth up to $5.8bn

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders. Additionally, Mirati shareholders will also receive one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for t.

MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders

Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion.

News for Mirati Therapeutics Stock (MRTX)